Iohexol in lumbar myelography: preliminary results from an open, noncomparative multicenter clinical study.
This is a preliminary report of the first clinical trials using iohexol as a contrast agent in lumbar myelography. The study was noncomparative and involved 82 adult patients in four centers. Iohexol doses of 10-15 ml (180 mg I/ml) were administered and clinical and laboratory tests were performed before and at intervals during 48 hr after myelography. Side effects were noted in 29 (35%) of 82 patients. Spinal repuncture 6 or 24 hr after myelography was performed in 51 patients. No significant increases in cerebrospinal fluid parameters were seen. No seizures or spikes on electroencephalography were seen.
D000328:Adult; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000009:adverse effects; D006801:Humans; D007463:Iodobenzoates; D007472:Iohexol; D009192:Myelography / Q000379:methods*; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol